CTOs on the Move

Payformance Solutions

www.payformancesolutions.com

 
Why we`re excited: The mission for Payformance Solutions is simple. We aim to be a catalyst for payment transformation in the healthcare industry. Our proprietary software solutions allow payers and providers to focus on what really matters: providing patients with access to care that yields the best health outcomes, at the lowest costs. The healthcare industry is complex and fragmented. Payers and providers are faced with a lack of transparency and conflicting financial goals that fail to consider the health outcomes of patients. Payformance offers data-driven, turnkey software solutions that provide payers and providers with the technical tools and resources ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kevin Mehta
Chief Technology Officer Profile

Similar Companies

Healthcare Commons Inc

Healthcare Commons Inc is a Penns Grove, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coding Strategies Inc

Coding Strategies Inc is a Powder Springs, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

North Florida Regional Medical Center

North Florida Regional Medical Center is a Gainesville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hospice El Paso

Hospice El Paso, Inc. is a El Paso, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.